<DOC>
	<DOC>NCT01715428</DOC>
	<brief_summary>Incretin-based therapies have shown significant effects beyond those on glucose metabolism. We aim in the present study to evaluate the effects of liraglutide on several cardio-metabolic risk markers.</brief_summary>
	<brief_title>Liraglutide and Cardio-Metabolic Risk Markers</brief_title>
	<detailed_description>In details, we will evaluate the effects of liraglutide on carotid-intima media thickness, oxidative stress, ghrelin, heat shock proteins and lipoproteins.</detailed_description>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>patients with a diagnosis of type2 diabetes severe hepatic or renal diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>diabetes, cardiovascular risk</keyword>
</DOC>